These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 30674472)

  • 1. How I treat refractory chronic graft-versus-host disease.
    Sarantopoulos S; Cardones AR; Sullivan KM
    Blood; 2019 Mar; 133(11):1191-1200. PubMed ID: 30674472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
    Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of quality of life in patients with steroid-refractory chronic graft-versus-host disease treated with the mTOR inhibitor everolimus.
    Lutz M; Kapp M; Einsele H; Grigoleit GU; Mielke S
    Clin Transplant; 2014 Dec; 28(12):1410-5. PubMed ID: 25287756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
    Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
    Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study.
    Herrmann R; Sturm M; Shaw K; Purtill D; Cooney J; Wright M; Phillips M; Cannell P
    Int J Hematol; 2012 Feb; 95(2):182-8. PubMed ID: 22183779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
    Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria.
    Sato T; Ichinohe T; Kanda J; Yamashita K; Kondo T; Ishikawa T; Uchiyama T; Takaori-Kondo A
    Int J Hematol; 2011 Apr; 93(4):532-541. PubMed ID: 21465116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report.
    Carpenter PA; Kitko CL; Elad S; Flowers ME; Gea-Banacloche JC; Halter JP; Hoodin F; Johnston L; Lawitschka A; McDonald GB; Opipari AW; Savani BN; Schultz KR; Smith SR; Syrjala KL; Treister N; Vogelsang GB; Williams KM; Pavletic SZ; Martin PJ; Lee SJ; Couriel DR
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1167-87. PubMed ID: 25838185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
    Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
    Saillard C; Crocchiolo R; Furst S; El-Cheikh J; Castagna L; Signori A; Oudin C; Faucher C; Lemarie C; Chabannon C; Granata A; Blaise D
    Leuk Lymphoma; 2014 May; 55(5):1106-12. PubMed ID: 23822538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews.
    Merkel EC; Mitchell SA; Lee SJ
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):752-758. PubMed ID: 26751003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide for salvage therapy of chronic graft-versus-host disease: a retrospective analysis.
    Fante MA; Holler B; Weber D; Angstwurm K; Bergler T; Holler E; Edinger M; Herr W; Wertheimer T; Wolff D
    Ann Hematol; 2020 Sep; 99(9):2181-2190. PubMed ID: 32715339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abatacept as salvage therapy in chronic graft-versus-host disease-a retrospective analysis.
    Wertheimer T; Dohse M; Afram G; Weber D; Heidenreich M; Holler B; Kattner AS; Neubauer A; Mielke S; Ljungman P; Holler E; Herr W; Edinger M; Martínez AP; Fante M; Wolff D
    Ann Hematol; 2021 Mar; 100(3):779-787. PubMed ID: 33515310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.
    Zeiser R; Burchert A; Lengerke C; Verbeek M; Maas-Bauer K; Metzelder SK; Spoerl S; Ditschkowski M; Ecsedi M; Sockel K; Ayuk F; Ajib S; de Fontbrune FS; Na IK; Penter L; Holtick U; Wolf D; Schuler E; Meyer E; Apostolova P; Bertz H; Marks R; Lübbert M; Wäsch R; Scheid C; Stölzel F; Ordemann R; Bug G; Kobbe G; Negrin R; Brune M; Spyridonidis A; Schmitt-Gräff A; van der Velden W; Huls G; Mielke S; Grigoleit GU; Kuball J; Flynn R; Ihorst G; Du J; Blazar BR; Arnold R; Kröger N; Passweg J; Halter J; Socié G; Beelen D; Peschel C; Neubauer A; Finke J; Duyster J; von Bubnoff N
    Leukemia; 2015 Oct; 29(10):2062-8. PubMed ID: 26228813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of chronic graft-versus-host disease.
    Arora M
    Best Pract Res Clin Haematol; 2008 Jun; 21(2):271-9. PubMed ID: 18503992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease.
    Akpek G; Lee SM; Anders V; Vogelsang GB
    Biol Blood Marrow Transplant; 2001; 7(9):495-502. PubMed ID: 11669216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chronic graft-versus-host-disease involving the oral mucosa: clinical presentation and treatment].
    Elad S; Levitt M; M Y S
    Refuat Hapeh Vehashinayim (1993); 2008 Nov; 25(4):19-27, 72. PubMed ID: 19263864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic graft-versus-host disease in children and adolescents with thalassemia after hematopoietic stem cell transplantation.
    Lertkovit O; Anurathapan U; Hongeng S; Thokanit NS; Pakakasama S
    Int J Hematol; 2021 Apr; 113(4):556-565. PubMed ID: 33385291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors for Permanent Discontinuation of Systemic Immunosuppression in Severely Affected Chronic Graft-Versus-Host Disease Patients.
    Curtis LM; Pirsl F; Steinberg SM; Mitchell SA; Baird K; Cowen EW; Mays J; Buxbaum NP; Pichard DC; Im A; Avila D; Taylor T; Fowler DH; Gress RE; Pavletic SZ
    Biol Blood Marrow Transplant; 2017 Nov; 23(11):1980-1988. PubMed ID: 28797782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.